

Macular Degeneration Guideline Committee – development

Date: 25/11/2015

Location: NICE offices, London

Minutes: Draft

Committee members present:		
Waqar Shah (Chair)		Present for all items
Mary-Ann Sherratt (MAS)		Present for all items
Jennifer Evans (JE)		Present for all items
Elizabeth Wick (EW)		Present for all items
Cathie Burke (CB)		Present for all items
Carol McCletchie (CM)		Present for all items
Alexander Foss (AF)		Present for all items
Katy Barnard (KB)		Present for all items
Ellen Rule (ER)		Present for all items
Andy Charley (AC)		Present for all items
Mary Freeman (MF)		Present for all items
Cathy Yelf (CY)		Present for all items

In attendance:		
Caroline Keir (CK)	NICE – Guideline Commissioning Manager	Present for all items
Stephen Duffield (SD)	ICG – Technical Analyst	Present for all items
Sue Spiers (SS)	ICG – Associate Director	Present for all items
Gabriel Rogers (GR)	ICG – Technical Advisor (HE)	Present for all items

Macular Degeneration Guideline Committee 3 minutes

Chris Gibbons (CG)	ICG – Technical Analyst (HE)	Present for all items
Dave Nicholls	NICE – Information Specialist	Present for all items
Anne Louise Clayton (A-LC)	NICE – Medicine Senior Editor	Present for items 1 and 2
Hugh McGuire (HM)	ICG – Technical Advisor	Present for all items
Sue Ellerby (SE)	ICG – Clinical Advisor	Present for all items

Observers:

Sarah Mills (SM)	ICG – Project Manager
Aimely Lee (AL)	ICG – Technical Analyst
Vonda Murray (VM)	ICG – Project Manager

Apologies:

Judith Hughes (JH)	PhD student
--------------------	-------------

1. Introductions and objectives for the meeting

The Chair welcomed the Committee members and attendees to the third meeting on age-related macular degeneration (AMD). The Committee members and attendees introduced themselves.

Apologies for the meeting were received as detailed above.

The Chair outlined the proposed objectives of the meeting, which included:

- The role of the senior editor
- Information on understanding data analysis
- Presentation of review question on risk factors for developing or progression of AMD
- Discussion regarding priorities for health economic modelling
- Agreement of review protocols

The Chair highlighted the importance of declaring conflicts of interest. He asked each attendee to declare any new conflicts since the previous meeting. No new conflicts were declared. Having reviewed the historical declaration of interests table it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The Chair asked the committee for any comments regarding accuracy of the minute of the last meeting. Other than noting that the draft minutes had stated that the next meeting was to take place in Manchester the minutes were agreed as an accurate record.

2. Role of the senior editor

A-LC presented information on the role of the editorial team in developing

clinical guidelines and provided

3. Prognostic reviews, hazard ratios, making recommendations

SD's presentation informed the committee of the methodology used by the technical team to quality assure and present the evidence for individual review questions including the rationale employed to inform inclusion / exclusion criteria for RQ2.

During the discussion of the evidence it was agreed that AF would be invited to give a short presentation to the committee at the next meeting detailing the disease progression for AMD.

Action – VM to add this as an agenda item for the next meeting

4. RQ2 – What risk factors increase the likelihood of a person developing AMD or progressing to late AMD?

SD presented the evidence identified for this review question. The Committee discussed the evidence, agreed the proposed evidence statements and made a draft recommendation based on the evidence and their own clinical experience / expertise. It was noted that the outcomes of this review question would be strongly linked to a number of other review questions and would possibly need to be revisited at a later date when considering related evidence.

5. Health economics

CG presented an update on the proposed health economic proposals for the guideline. The committee agreed with the rationale and proposed plans for health economics.

6 and 7. Agreeing review protocols

SD presented a number of draft review protocols for consideration and agreement by the committee. Protocols for the following review questions were agreed:

RQ19 How often should people with early AMD, intermediate AMD or advanced geographic atrophy be reviewed?

RQ20 How often should people with early AMD, intermediate AMD or advanced geographic atrophy have their non-affected eye reviewed?

RQ21 In people with neovascular AMD for whom treatment has been deferred how often should they be reviewed?

It was agreed that the wording of the above review question be amended to “In people with neovascular AMD who are not being actively treated how often should they be reviewed?” This will enable people who have been discharged due to quiescent AMD to be captured in the population of interest.

RQ22 How often should people with neovascular AMD have their non-affected eye reviewed?

RQ9 What is the effectiveness of support strategies for people with visual impairment and AMD (for example reablement services and strategies for optimising existing visual performance)?

RQ17 What are the barriers to appointment attendance and uptake of treatment for people with AMD?

8. Next steps

SS informed the committee that SD would write up the discussion for RQ2 and this, together with the agreed review protocols would be circulated to the committee for comment ahead of the next meeting.

The Chair thanked the committee for their time and contribution to the meeting. The venue, date and time of the next meeting was confirmed.

For information – Upcoming dates of NICE’s Health Economics Workshops (London office)

Wed 9th March 2016

Macular Degeneration Guideline Committee 3 minutes

Tues 17th May 2016

Wed 27th July 2016

Wed 28th September 2016

Wed 30th November 2016

Date of next meeting: Wednesday 13 January 2016

Location of next meeting: NICE offices, London